AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.
| Revenue (Most Recent Fiscal Year) | $28.83M |
| Net Income (Most Recent Fiscal Year) | $-162.86M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 51.08 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.67 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -604.66% |
| Net Margin (Trailing 12 Months) | -511.88% |
| Return on Equity (Trailing 12 Months) | -16.17% |
| Return on Assets (Trailing 12 Months) | -12.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.07 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.07 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.58 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.55 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.55 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 298.83M |
| Free Float | 212.47M |
| Market Capitalization | $1.68B |
| Average Volume (Last 20 Days) | 5.56M |
| Beta (Past 60 Months) | 0.69 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 28.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.42% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |